Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

March 1, 2021 Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of tumor-infiltrating lymphocytes (TILs) can help evaluating the efficacy of novel immunotherapy agents. LEARN MORE
November 6, 2020 In Vivo Imaging of Syngeneic Models for Immuno-Oncology Studies Explore how different imaging modalities are used to monitor in vivo immuno-oncology (I/O) studies in syngeneic tumor ... LEARN MORE
July 16, 2020 Next Generation Sequencing 101 A look at the range of next-generation sequencing technologies available today including whole genome, RNA, and whole ... LEARN MORE
April 24, 2020 Modeling Oncogenic RAS and BRAF Mutations Using Colorectal Cancer Organoids Explore how genetically engineered patient-derived tumor organoids are helping to model colorectal cancer and specific ... LEARN MORE
February 11, 2020 huPBMC Humanized Mouse Models: De-Risking Graft versus Tumor (GvT) Effects Through a Co-Culture Donor Selection Assay Explore how to use a donor selection assay to limit the chances of graft vs tumor (GvT) effects when using huPBMC ... LEARN MORE
October 24, 2019 Graft-versus-Host Disease: Types and How to Model Them Review the different types of graft-versus-host disease (GvHD) and the preclinical models (including humanized mice) ... LEARN MORE
July 26, 2019 Targeting the CD47/SIRPɑ Axis in Cancer Immunotherapy Explore why the CD47/SIRPα axis is an important immuno-oncology target and the methods being used to block this axis. LEARN MORE
March 14, 2019 LAG3: A Promising New Cancer Immunotherapy Target As we continue our discussion of the immune revolution in cancer therapy, we look at the benefits of targeting LAG3, an ... LEARN MORE
February 7, 2019 CD40: Targeting Co-Stimulatory Pathways for Cancer Immunotherapy Explore the role of CD40 in cancer immunotherapy, including its background, functions, and why combination regimens may ... LEARN MORE